SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The stock is trending due to heightened speculation around impending Phase 3 results for its lead AML immunotherapy, GPS, with the CEO's recent remarks on "curative outcomes" fueling strong community belief in a positive data readout and potential buyout. This has intensified discussions of a significant short squeeze as institutional accumulation is noted and the stock approaches new highs.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid intense community speculation of an impending short squeeze, driven by perceived technical breakouts and widespread anticipation of strategic announcements or positive earnings from Chairman Ryan Cohen, with many noting its resilience in a volatile market.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

ANTX is trending due to a cluster of recent positive developments including a $40 million private placement, new strategic partnerships with GSK and DNDi, and an analyst upgrade, sparking intense community debate between aggressive bulls targeting significant price appreciation and bears pointing to past trial setbacks and potential dilution.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating Middle East tensions, particularly the Strait of Hormuz closure and production cuts by key oil producers, have sent crude prices soaring. Community discussion is highly polarized, with some anticipating further parabolic gains, while others foresee a sharp pullback as G7 nations consider a significant strategic oil reserve release and potential escort missions to reopen the strait.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating Middle East tensions and surging oil prices fuel expectations for increased market volatility, with the community sharply divided between those buying dips as a market hedge and others anticipating a "VIX crush" or inherent decay in the leveraged ETF.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 trial data for its bladder cancer candidate, NDV-01, which reported a durable 76% complete response rate and reinforced plans for Phase 3 trials. The company's recently announced $160 million private placement to fund further development is also a key talking point, with the community actively discussing the drug's potential and the financing's implications for its future trajectory.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

Aureus Greenway Holdings is trending due to its announced merger with drone manufacturer Powerus, backed by Eric and Donald Trump Jr., signaling a significant pivot into the defense-drone sector amid rising military tech demand. Community discussion reflects strong enthusiasm for potential government contracts and short squeeze opportunities, while also acknowledging concerns around the stated merger valuation and recent share dilution.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is highly active as crude oil experiences significant volatility, with many traders anticipating a sharp downturn after recent geopolitical tensions led to price surges. The community is aggressively buying this inverse ETF, viewing current oil levels as overbought and primed for a major correction.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending after resolving its legal dispute with Novo Nordisk and announcing a partnership to offer FDA-approved GLP-1 weight-loss medications on its platform. This development has largely eliminated the previous bear thesis, fueling significant short-squeeze speculation and community discussion about the company's long-term potential as a digital health and wellness platform.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as it staged a notable rebound from an early dip driven by escalating Middle East tensions and oil price spikes, surprising many bears who had anticipated a market collapse amid reports of oil tankers transiting the Strait of Hormuz and discussions of G7 reserve releases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Citigroup Inc.

Citigroup Inc. decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 63.4% during the 3rd quarter, according to its most recent filing with the Securities...

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC cut its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 39.9% during the third quarter, according to its most recent Form 13F filing with...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 8% - What's Next?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 8% - What's Next...

Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined a busy slate of clinical catalysts and a growing commercial footprint during a presentation at TD Cowen's 46th Annual Healthcare...

Erste Asset Management GmbH Has $2.47 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Erste Asset Management GmbH boosted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 55.3% in the third quarter, according to the company in its most recent filing with the...

Arrowhead Pharmaceuticals, Inc. $ARWR Position Increased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 90.3% during the third quarter, according to its most recent Form 13F filing with the...

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.

Vanguard Group Inc. Has $553.08 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Vanguard Group Inc. lifted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and...

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual Health Care Conference March 2-4, 2026 Type...

Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by King Luther Capital Management Corp

King Luther Capital Management Corp increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 54.7% during the 3rd quarter, according to the company in its...

Arrowhead Pharmaceuticals Inc.

Leerink Global Healthcare Conference 2026

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Current Price	$58.62
Prev Close	$59.82
Open	$58.20
Dividend Yield	0.00%
50-Day Moving Average	$65.78
Beta	1.53
Avg. Volume	3.65M
PE Ratio	38.89

52-Week High	$76.76
52-Week Low	$9.57
Market Capitalization	$8.38B
EPS (Annual)	-$0.0122
Price to Book	14.46
Revenue Per Employee	$1.17M

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARWR News

ARWRArrowhead Pharmaceuticals Inc.